0000000000634261

AUTHOR

Sandra Heskamp

0000-0001-7250-0846

showing 2 related works from this author

89 Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89 Zr Radiochemistry

2017

Contains fulltext : 181624.pdf (Publisher’s version ) (Open Access) Immuno-positron emission tomography (immunoPET) with (89)Zr-labeled antibodies has shown great potential in cancer imaging. It can provide important information about the pharmacokinetics and tumor-targeting properties of monoclonal antibodies and may help in anticipating on toxicity. Furthermore, it allows accurate dose planning for individualized radioimmunotherapy and may aid in patient selection and early-response monitoring for targeted therapies. The most commonly used chelator for (89)Zr is desferrioxamine (DFO). Preclinical studies have shown that DFO is not an ideal chelator because the (89)Zr-DFO complex is partly…

Pathologymedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentmonoclonal-antibodiesBiomedical Engineeringrational designPharmaceutical Sciencebifunctional chelating-agentBioengineeringCancer imagingReviewgrowth-factorRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]010402 general chemistryMonoclonal antibody01 natural sciencesDose planningp-isothiocyanatobenzyl-desferrioxamineIn vivo[ CHIM.ORGA ] Chemical Sciences/Organic chemistryimmuno-petmedicineIn patient[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacologymedicine.diagnostic_test010405 organic chemistrybusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryOrganic Chemistrydrug development3. Good health0104 chemical sciencesDrug developmentPositron emission tomographyRadioimmunotherapyUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]click chemistryCancer researchmetastatic breast-cancerbusinessbearing nude-miceNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]BiotechnologyBioconjugate Chemistry
researchProduct

Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging

2020

Contains fulltext : 220838.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Lately, zirconium-89 has shown great promise as a radionuclide for PET applications of long circulating biomolecules. Here, the design and synthesis of protracted and long-lived GLP-1 receptor agonists conjugated to desferrioxamine and labelled with zirconium-89 is presented with the purpose of studying their in vivo distribution by PET imaging. The labelled conjugates were evaluated and compared to a non-labelled GLP-1 receptor agonist in both in vitro and in vivo assays to certify that the modification did not significantly alter the peptides' structure or function. Finally, the zirconium-89 labelled peptide…

AgonistCancer ResearchBiodistributionmedicine.drug_class[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingPeptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineChemistry Techniques SyntheticPharmacologyRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]Glucagon-Like Peptide-1 Receptor030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineIn vivomedicineRadiology Nuclear Medicine and imagingTissue DistributionAmino Acid SequenceReceptorGlucagon-like peptide 1 receptorchemistry.chemical_classificationRadioisotopesRadiochemistryChemistryIn vitro toxicology030220 oncology & carcinogenesisDrug DesignIsotope LabelingPositron-Emission Tomography[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyMolecular MedicineZirconiumPeptidesNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Ex vivoHalf-Life
researchProduct